# FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Bolzon Bradley J PhD					2. Issuer Name and Ticker or Trading Symbol Black Diamond Therapeutics, Inc. [ BDTX ]								Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director X 10% Owner     Officer (give title Other (specify)					
(Last) (First) (Middle) C/O BLACK DIAMOND THERAPEUTICS, INC. 139 MAIN STREET					3. Date of Earliest Transaction (Month/Day/Year) 12/14/2020									w) ``		belov	w)`	
(Street) CAMBRIDGE MA 02142				4. 11										Individual or Joint/Group Filing (Check Applicable ne)  X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	tate) (	Zip)															
		Table	l - Non-Deriva	ative	Secu	rities	Ac	quire	d, Di	sposed of	f, or B	enefi	cially Owr	ned				
1. Title of Security (Instr. 3)			2. Transacti Date (Month/Day		2A. Deemed Execution Date, if any (Month/Day/Year)		·	3. Transaction Code (Instr. 8)		4. Securities Acquired Disposed Of (D) (Instr. 5)		ed (A) or tr. 3, 4 a	nd Securitie Beneficia Owned F	5. Amount of Securities Beneficially Owned Following Reported		Direct      ndirect      tr. 4)	7. Nature of Indirect Beneficial Ownership	
								Code	v	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)			(Instr. 4)	
Common	Stock		12/14/20	020				J <sup>(1)</sup>		20,784	D	\$0.0	00 822	2,140 I			See Footnote <sup>(2)</sup>	
Common	Stock		12/14/20	020				J <sup>(3)</sup>		310	A	\$0.0	00 3:	10			See Footnote <sup>(4)</sup>	
Common Stock			12/14/20	12/14/2020				J <sup>(5)</sup>		310	D	\$0.0	00 (	)			See Footnote <sup>(4)</sup>	
Common Stock			12/14/20	12/14/2020				J <sup>(6)</sup>		307	A	\$0.0	00 30	)7			See Footnote <sup>(7)</sup>	
Common Stock 12/1			12/14/20	020				J <sup>(8)</sup>		307	D	\$0.0	00 (	0		See Footnote <sup>(7)</sup>		
Common Stock 12/14/2			020	20			J <sup>(9)</sup>		11	A	\$0.0	0.00 21,85		. D				
Common Stock													3,947	7,941	I		See Footnote <sup>(10)</sup>	
Common Stock												1,277	7,541			See Footnote <sup>(11)</sup>		
Common Stock											380	,942			See Footnote <sup>(12)</sup>			
		Та	ble II - Derivat (e.g., p							oosed of, convertib				ed				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any (Month/Day/Year)	4. Trans	saction (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration (Month/Day		rcisable and Date	7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)	
				Code	· v	(A)	(D)	Date Exerc	cisable	Expiration Date	Title	Amount or Number of Shares	er					
Explanatio	n of Respor	ises:	•		1					,						,		

- 1. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I, L.P. ("Versant Vantage I"), to its partners, pursuant to a Rule 10b5-1 trading plan.
- 2. Shares held by Versant Vantage I, Versant Vantage I, GP, L.P. ("Versant Vantage I GP, L.P. ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is be general partner of Versant Vantage I, The Reporting Person is a managing member of Versant Vantage I, however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
- 3. Represents a change in the form of ownership of Versant Vantage I GP LP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Vantage I.
- 4. Shares held by Versant Vantage I GP LP. Versant Vantage I GP-GP is the general partner of Versant Vantage I GP LP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant Vantage I GP LP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary
- 5. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I GP LP, to its partners.
- 6. Represents a change in the form of ownership of Versant Vantage I GP-GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Vantage I GP LP.
- 7. Shares held by Versant Vantage I GP-GP. The Reporting Person is a managing member of Versant Vantage I GP-GP and may be deemed to share voting and dispositive power over the shares held Versant Vantage I GP-GP; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
- 8. Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Vantage I GP-GP, to its members.

- 9. Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by Versant Vantage I GP-GP.
- 10. Shares held by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VI; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.
- 11. Shares held by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company ("Versant Voyageurs I GP") is the general partner of Versant Voyageurs I. The Reporting Person may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein
- 12. Shares held by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). Versant Voyageurs I GP LP is the general partner of Versant I Parallel. Versant Ventures VI GP is the general partner of Versant Voyageurs I GP LP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein.

#### Remarks

/s/ Robin L. Praeger, Attorney-in-fact for Bradley J. 12/16/2020 Bolzon, PhD.

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.